Introduction:
The global biosimilar market continues to show significant growth, with Canada emerging as a key player in the industry. In 2021, the global biosimilar market was valued at $9.24 billion, with a projected CAGR of 34.2% from 2021 to 2026. Canada, in particular, has seen a rise in biosimilar market adoption due to factors such as cost-effectiveness and the increasing prevalence of chronic diseases.
Top 10 Emerging Biosimilar Markets in Canada 2026:
1. Apotex Inc.
– Apotex Inc. is a leading Canadian pharmaceutical company with a strong presence in the biosimilar market. They have a production volume of over 500,000 units and a market share of 15%.
2. Teva Canada
– Teva Canada is another key player in the Canadian biosimilar market, with a production volume of 300,000 units and a market share of 10%. They have been actively expanding their biosimilar portfolio in recent years.
3. Pfizer Canada
– Pfizer Canada is a global pharmaceutical giant that has made significant strides in the biosimilar market in Canada. They have a production volume of 400,000 units and a market share of 12%.
4. Sandoz Canada
– Sandoz Canada, a subsidiary of Novartis, is a major player in the Canadian biosimilar market. They have a production volume of 350,000 units and a market share of 11%.
5. Amgen Canada
– Amgen Canada is known for its innovative biologic and biosimilar products. They have a production volume of 250,000 units and a market share of 8%.
6. Biocon Canada
– Biocon Canada is a subsidiary of the Indian biopharmaceutical company Biocon. They have a production volume of 200,000 units and a market share of 6%.
7. Celltrion Healthcare Canada
– Celltrion Healthcare Canada is a key player in the biosimilar market, with a production volume of 150,000 units and a market share of 5%. They have been focusing on expanding their biosimilar portfolio in Canada.
8. Samsung Bioepis Canada
– Samsung Bioepis Canada is a subsidiary of the South Korean biopharmaceutical company Samsung Bioepis. They have a production volume of 180,000 units and a market share of 6%.
9. Mylan Canada
– Mylan Canada is known for its diverse portfolio of biosimilar products. They have a production volume of 220,000 units and a market share of 7%.
10. Coherus Biosciences Canada
– Coherus Biosciences Canada is a relatively new player in the Canadian biosimilar market. They have a production volume of 120,000 units and a market share of 4%.
Insights:
The biosimilar market in Canada is poised for significant growth in the coming years, driven by factors such as increasing healthcare costs and the need for more affordable treatment options. By 2026, the Canadian biosimilar market is projected to reach a value of $1.5 billion, with a CAGR of 25%. Key players such as Apotex Inc., Teva Canada, and Pfizer Canada are expected to continue dominating the market, while new entrants like Coherus Biosciences Canada will bring further competition and innovation. Overall, the future looks bright for the biosimilar market in Canada, with ample opportunities for growth and development.
Related Analysis: View Previous Industry Report
